Jerini
Peptidomimetics and small molecules as drug candidates
![jerini Logo jerini Logo](https://www.bmp.com/wp-content/uploads/2022/06/jerini-logo-rgb.svg 1x, https://www.bmp.com/wp-content/uploads/2022/06/jerini-logo-rgb.svg 2x)
About Jerini
The peptide experts
With its technology platform Peptides-to-Drugs (P2D) the biotechnology company pursued disease indications for which limited, inadequate, or no treatment options exist, most notably within the ophthalmology, oncology and inflammatory therapeutic areas.
Management
Jens Schneider-Mergener
bmp Ventures Team
Founded
1994
Invested
2000
Stage
Expansion
Industry
Life Sciences & eHealth
Status
Exited (2005 – IPO)